Back to Search Start Over

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Authors :
Halimi JM
Sarafidis P
Azizi M
Bilo G
Burkard T
Bursztyn M
Camafort M
Chapman N
Cottone S
de Backer T
Deinum J
Delmotte P
Dorobantu M
Doumas M
Dusing R
Duly-Bouhanick B
Fauvel JP
Fesler P
Gaciong Z
Gkaliagkousi E
Gordin D
Grassi G
Grassos C
Guerrot D
Huart J
Izzo R
Águila FJ
Járai Z
Kahan T
Kantola I
Kociánová E
Limbourg FP
Lopez-Sublet M
Mallamaci F
Manolis A
Marketou M
Mayer G
Mazza A
MacIntyre IM
Mourad JJ
Muiesan ML
Nasr E
Nilsson P
Oliveras A
Ormezzano O
Paixão-Dias V
Papadakis I
Papadopoulos D
Perl S
Polónia J
Pontremoli R
Pucci G
Robles NR
Rubin S
Ruilope LM
Rump LC
Saeed S
Sanidas E
Sarzani R
Schmieder R
Silhol F
Sokolovic S
Solbu M
Soucek M
Stergiou G
Sudano I
Tabbalat R
Tengiz I
Triantafyllidi H
Tsioufis K
Václavík J
van der Giet M
Van der Niepen P
Veglio F
Venzin RM
Viigimaa M
Weber T
Widimsky J
Wuerzner G
Zelveian P
Zebekakis P
Lueders S
Persu A
Kreutz R
Vogt L
Source :
Journal of hypertension [J Hypertens] 2024 Sep 01; Vol. 42 (9), pp. 1544-1554. Date of Electronic Publication: 2024 May 13.
Publication Year :
2024

Abstract

Objective: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear.<br />Methods: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality.<br />Results: Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 15-50%) had preexisting CKD, with 10% of them (5-30%) previously referred to a nephrologist, while 30% (15-40%) had resistant hypertension. The reported rate of previous recent (<6 months) estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) testing were 80% (50-95%) and 30% (15-50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70-90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20-40%] vs. 15% [10-25], P  = 0.003), GLP1-RA (10% [10-20%] vs. 5% [5-10%], P  = 0.003) and mineralocorticoid receptor antagonists (20% [10-30%] vs. 15% [10-20%], P  = 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries.<br />Conclusions: Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1473-5598
Volume :
42
Issue :
9
Database :
MEDLINE
Journal :
Journal of hypertension
Publication Type :
Academic Journal
Accession number :
38747416
Full Text :
https://doi.org/10.1097/HJH.0000000000003756